Emerging applications of CRISPR/Cas9 gene editing technology in reversing drug resistance in oral squamous cell carcinoma.
Oral oncology, 134: 106100 PMID 36063701 DOI 10.1016/j.oraloncology.2022.106100
Abstract
This article has no abstract in PubMed.